MDM-2/p53

The p53 tumor suppressor is a principal mediator of growth arrest, senescence, and apoptosis in response to a broad array of cellular damage. p53 is a short-lived protein that is maintained at low, often undetectable, levels in normal cells. Under stress conditions, the p53 protein accumulates in the cell, binds in its tetrameric form to p53-response elements and induces the transcription of various genes.

MDM-2 is transcriptionally activated by p53 and MDM-2, in turn, inhibits p53 activity in several ways. MDM-2 binds to the p53 transactivation domain and thereby inhibits p53-mediated transactivation. MDM-2 also contains a signal sequence that is similar to the nuclear export signal of various viral proteins and, after binding to p53, it induces its nuclear export. As p53 is a transcription factor, it needs to be in the nucleus to be able to access the DNA; its transport to the cytoplasm by MDM-2 prevents this. Finally, MDM-2 is a ubiquitin ligase, so is able to target p53 for degradation by the proteasome.

In many tumors p53 is inactivated by the overexpression of the negative regulators MDM2 and MDM4 or by the loss of activity of the MDM2 inhibitor ARF. The pathway can be reactivated in these tumors by small molecules that inhibit the interaction of MDM2 and/or MDM4 with p53. Such molecules are now in clinical trials.



Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

ABL-L

Cat. No.: HY-142913

ABL-L induces apoptosis of human laryngocarcinoma cells through p53-dependent pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Alrizomadlin

(APG-115; AA-115)

Cat. No.: HY-101518

Alrizomadlin (APG-115) is an orally active **MDM2** protein inhibitor binding to MDM2 protein with IC_{50} and K_i values of 3.8 nM and 1 nM, respectively. Alrizomadlin blocks the interaction of MDM2 and p53 and induces cell-cycle arrest and **apoptosis** in a p53-dependent manner.



Purity: 98.16%
Clinical Data: Phase 2
Size: 1 mg, 5 mg, 10 mg

AM-8735

Cat. No.: HY-12734

AM-8735 is a potent and selective **MDM2** inhibitor with an IC_{50} of 25 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Amifostine

(WR2721)

Cat. No.: HY-B0639

Amifostine (WR2721) is a broad-spectrum cytoprotective agent and a radioprotector. Amifostine selectively protects normal tissues from damage caused by radiation and chemotherapy. Amifostine is potent **hypoxia-inducible factor-α1 (HIF-α1)** and **p53** inducer.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Amifostine thiol

(WR-1065)

Cat. No.: HY-137864

Amifostine thiol (WR-1065) is an active metabolite of the cytoprotector Amifostine (HY-B0639). Amifostine thiol is a cytoprotective agent with radioprotective abilities. Amifostine thiol activates p53 through a JNK-dependent signaling pathway.



Purity: ≥90.0%
Clinical Data: No Development Reported
Size: 10 mg

Amifostine thiol dihydrochloride

(WR-1065 dihydrochloride)

Cat. No.: HY-103640

Amifostine thiol (WR-1065) dihydrochloride can protect normal tissues from the toxic effects of certain cancer drugs and activate **p53** through a JNK-dependent signaling pathway.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Amifostine thiol-d4 dihydrochloride

Cat. No.: HY-103640S

Amifostine thiol-d4 dihydrochloride is the deuterium labeled Amifostine thiol dihydrochloride.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Amifostine thiol-d6 dihydrochloride

Cat. No.: HY-103640S1

Amifostine thiol-d6 dihydrochloride is the deuterium labeled Amifostine thiol dihydrochloride.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Amifostine trihydrate

(WR2721 trihydrate)

Cat. No.: HY-B0639A

Amifostine trihydrate (WR2721 trihydrate) is a broad-spectrum cytoprotective agent and a radioprotector. Amifostine trihydrate selectively protects normal tissues from damage caused by radiation and chemotherapy.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Anticancer agent 42

Cat. No.: HY-146516

Anticancer agent 42 (compound 10d) is an orally active anticancer agent, and shows a potent antitumor activity against MDA-MB-231 cell with an IC_{50} of 0.07 μM. Anticancer agent 42 can exert its anticancer activity by activating apoptotic pathway and **p53** expression.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Antitumor agent-55

Cat. No.: HY-146038

Antitumor agent-55 (compound 5q) is a potent antitumor agent. Antitumor agent-55 effectively inhibits PC3, with an IC_{50} of 0.91 μM. Antitumor agent-55 effectively inhibits the colony formation, suppresses the cell migration in PC3.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BH3I-1

(BHI1; BH 3I1)

Cat. No.: HY-100383

BH3I-1 is a **Bcl-2 family** antagonist, which inhibits the binding of the **Bak** BH3 peptide to **Bcl-xL** with a K_i of 2.4±0.2 μM in FP assay. BH3I-1 has a K_d of 5.3 μM against the **p53/MDM2** pair.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BI-0252

Cat. No.: HY-100765

BI-0252 is an orally active, selective **MDM2-p53** inhibitor with an IC_{50} of 4 nM. BI-0252 can induce tumor regressions in all animals of a mouse SJSA-1 xenograft, with concomitant induction of the tumor protein p53 (TP53) target genes and markers of apoptosis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CBL0137 hydrochloride

(Curaxin-137 hydrochloride; CBL-C137 hydrochloride)

Cat. No.: HY-18935A

CBL0137 hydrochloride is an inhibitor of the histone chaperone, **FACT**. CBL0137 hydrochloride can also activate **p53** and inhibits **NF-κB** with EC_{50}s of 0.37 and 0.47 μM, respectively.



Purity: 99.21%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

Cjoc42

Cat. No.: HY-138054

Cjoc42 is a compound capable of binding to gankyrin. Cjoc42 inhibits gankyrin activity in a dose-dependent manner. Cjoc42 prevents the decrease in p53 protein levels normally associated with high amounts of gankyrin.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

COTI-2

Cat. No.: HY-19896

COTI-2, an anti-cancer drug with low toxicity, is an orally available third generation activator of **p53 mutant** forms. COTI-2 acts both by reactivating mutant p53 and inhibiting the **PI3K/AKT/mTOR** pathway. COTI-2 induces **apoptosis** in multiple human tumor cell lines.



Purity: 98.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CP-31398 dihydrochloride

Cat. No.: HY-18343A

CP-31398 dihydrochloride stabilizes the active conformation of **p53** and promotes p53 activity in cancer cell lines with mutant or wild-type p53.



Purity: 99.16%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CTX1

Cat. No.: HY-U00442

CTX1 is a **p53** activator that overcomes HdmX-mediated p53 repression. CTX1 exhibits potent anti-cancer activity in a mouse acute myeloid leukemia (AML) model system.



Purity: ≥96.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg

DPBQ

Cat. No.: HY-U00441

DPBQ activates **p53** and triggers **apoptosis** in a polyploid-specific manner, but does not inhibit topoisomerase or bind DNA. DPBQ elicits expression and phosphorylation of p53 and this effect is specific to tetraploid cells.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg

Eprenetapopt

(APR-246; PRIMA-1Met)

Cat. No.: HY-19980

Eprenetapopt (APR-246) is a first-in-class, small molecule that restores wild-type p53 functions in TP53-mutant cells. Eprenetapopt triggers apoptosis in tumor cells.



Purity: ≥98.0%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GEM-5

Cat. No.: HY-146540

GEM-5 is a gemcitabine-based conjugate containing a **HIF-1α** inhibitor (YC-1) (IC_{50}=30 nM). GEM-5 can significantly down-regulate the expression of **HIF-1α** and up-regulate the expression of tumor suppressor **p53**. GEM-5 induces the **apoptosis** of A2780 cells and inhibits tumor growth.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HLI373

Cat. No.: HY-108640

HLI373 is an efficacious **Hdm2** inhibitor. HLI373 inhibits the ubiquitin ligase activity of Hdm2. HLI373 is effective in inducing **apoptosis** of several tumor cells that are sensitive to DNA-damaging agents. **Antimalarial** activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

HLI373 dihydrochloride

Cat. No.: HY-108640A

HLI373 dihydrochloride is an efficacious **Hdm2** inhibitor. HLI373 dihydrochloride inhibits the ubiquitin ligase activity of Hdm2. HLI373 dihydrochloride is effective in inducing **apoptosis** of several tumor cells that are sensitive to DNA-damaging agents. **Antimalarial** activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Idasanutlin

(RG7388)

Cat. No.: HY-15676

Idasanutlin (RG7388) is a potent and selective **MDM2** antagonist, inhibiting p53-MDM2 binding, with an IC_{50} of 6 nM.



Purity: 99.90%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Inauhzin

(INZ)

Cat. No.: HY-15869

Inauhzin is a dual **SirT1/IMPDH2** inhibitor, and acts as an activator **p53**, used in the research of cancer.



Purity: 99.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ivaltinostat

(CG-200745)

Cat. No.: HY-16138

Ivaltinostat (CG-200745) is an orally active, potent pan-**HDAC** inhibitor which has the hydroxamic acid moiety to bind zinc at the bottom of catalytic pocket. Ivaltinostat inhibits deacetylation of histone H3 and tubulin.



Purity: >98%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ivaltinostat formic

(CG-200745 formic)

Cat. No.: HY-16138A

Ivaltinostat (CG-200745) formic is an orally active, potent pan-**HDAC** inhibitor which has the hydroxamic acid moiety to bind zinc at the bottom of catalytic pocket. Ivaltinostat formic inhibits deacetylation of histone H3 and tubulin.



Purity: 99.36%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

Kevetrin hydrochloride (4-Isothioureidobutyronitrile hydrochloride; ...)

Cat. No.: HY-16271

Kevetrin hydrochloride is a small molecule and activator of the tumor suppressor protein p53, with potential antineoplastic activity.



Purity: ≥98.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 500 mg

KYP-2047

Cat. No.: HY-100475

KYP-2047 is a potent and BBB-penetrating **prolyl-oligopeptidase (POP)** inhibitor, with an K_i value of 0.023 nM. KYP-2047 reduces glioblastoma proliferation through angiogenesis and apoptosis modulation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MA242

Cat. No.: HY-112816

MA242 is a specific dual inhibitor of **MDM2** and **NFAT1**. MA242 directly binds both MDM2 and NFAT1 with high affinity, induces their protein degradation, and inhibits NFAT1-mediated transcription of MDM2.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MA242 free base

Cat. No.: HY-112816A

MA242 free base is a specific dual inhibitor of **MDM2** and **NFAT1**. MA242 free base directly binds both MDM2 and NFAT1 with high affinity, induces their protein degradation, and inhibits NFAT1-mediated transcription of MDM2.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MB710

Cat. No.: HY-120373

MB710, an aminobenzothiazole derivative, is a stabilizer of oncogenic **p53 mutation Y220C**. MB710 binds tightly to the Y220C pocket and stabilizes **p53-Y220C**, with a K_d of 4.1 μM. MB710 shows anticancer activity in p53-Y220C cell lines.



Purity: 98.09%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

MC-VC-PABC-SP 141

Cat. No.: HY-136320

MC-VC-PABC-SP 141 is a **drug-linker conjugate for ADC** with potent antitumor activity by using SP 141 (a potent MDM2 inhibitor), linked via the cleavable ADC linker MC-VC-PABC.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MD-222

Cat. No.: HY-134823

MD-222 is the first-in-class highly potent PROTAC degrader of **MDM2**. MD-222 consists of ligands for **Cereblon** and **MDM2**. MD-222 induces rapid degradation of the **MDM2** protein and activation of wild-type p53 in cells. MD-222 has anticancer effects.



Purity: 99.28%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

MD-224

Cat. No.: HY-114312

MD-224 is a first-in-class and highly potent small-molecule human murine double minute 2 (**MDM2**) degrader based on the proteolysistargeting chimera (PROTAC) concept. MD-224 consists of ligands for **Cereblon** and **MDM2**.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MDM2-IN-1

Cat. No.: HY-130684

MDM2-IN-1 (Compound 30) is a synthetic **MDM2-p53 interaction (MDM2)** inhibitor and contains the trans (D-)configuration.



Purity: 95.13%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MDM2-IN-21

Cat. No.: HY-139458

MDM2-IN-21 is a potent **MDM2** inhibitor. MDM2-IN-21 can be used for the research of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MI-1061

Cat. No.: HY-125858

MI-1061 is a potent, orally bioavailable, and chemically stable **MDM2** (MDM2-p53 interaction) inhibitor (IC_{50}=4.4 nM; K_i=0.16 nM). MI-1061 potently activates **p53** and induces **apoptosis** in the SJSA-1 xenograft tumor tissue in mice. Anti-tumor activity.



Purity: 99.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

MI-1061 TFA

Cat. No.: HY-125858A

MI-1061 TFA is a potent, orally bioavailable, and chemically stable **MDM2** (MDM2-p53 interaction) inhibitor (IC_{50}=4.4 nM; K_i=0.16 nM). MI-1061 TFA potently activates **p53** and induces **apoptosis** in the SJSA-1 xenograft tumor tissue in mice. Anti-tumor activity.



Purity: 95.08%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

MI-773

Cat. No.: HY-17493

MI-773 is a potent **MDM2-p53** proteinprotein interaction (PPI) inhibitor with high binding affinity against MDM2 (K_d=8.2 nM). MI-773 has antitumor activity.



Purity: 98.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Milademetan

(DS-3032) Cat. No.: HY-101266

Milademetan (DS-3032) is a specific and orally active **MDM2** inhibitor for the research of acute myeloid leukemia (AML) or solid tumors. Milademetan (DS-3032) induces **G1 cell cycle arrest**, senescence and **apoptosis**.



Purity: 98.33%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Milademetan tosylate hydrate

(DS-3032b; DS-3032 tosylate hydrate) Cat. No.: HY-101266B

Milademetan (DS-3032) tosylate hydrate is a specific and orally active **MDM2** inhibitor for the research of acute myeloid leukemia (AML) or solid tumors. Milademetan (DS-3032) tosylate hydrate induces **G1 cell cycle arrest**, senescence and **apoptosis**.



Purity: 98.21%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MIRA-1

(NSC 19630) Cat. No.: HY-108639

MIRA-1 is a maleimide analogue. MIRA-1 can induce **apoptosis** in mutant p53 cells via restoration of p53-dependent transcriptional transactivation. MIRA-1 has anticancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MRT00033659

Cat. No.: HY-117857

MRT00033659 is a potent broad-spectrum kinase inhibitor of **CK1** (IC_{50}=0.9 μM for CK1δ) and **CHK1** (IC_{50}=0.23 μM). MRT00033659, a pyrazolo-pyridine analogue, induces **p53** pathway activation and E2F-1 destabilisation.



Purity: 99.18%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

MS7972

Cat. No.: HY-119053

MS7972 is a small molecule that blocks human p53 and CREB binding protein association. MS7972 can almost completely block this BRD interaction at 50 μM.



Purity: 99.81%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Mutant p53 modulator-1

Cat. No.: HY-145759

Mutant p53 modulator-1 is a mutant p53 modulator. Mutant p53 modulator-1 reduces the progression of cancers that contain a p53 mutation (extracted from patent WO2021231474A1, compound 231B).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MX69

Cat. No.: HY-100892

MX69 is an inhibitor of **MDM2/XIAP**, used for cancer treatment.



Purity: 99.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Navtemadlin

(AMG 232; KRT-232) Cat. No.: HY-12296

Navtemadlin (AMG 232) is a potent, selective and orally available inhibitor of **p53-MDM2** interaction, with an IC_{50} of 0.6 nM. Navtemadlin binds to MDM2 with a K_d of 0.045 nM.



Purity: 99.43%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Navtemadlin-d7

(AMG 232-d7; KRT-232-d7) Cat. No.: HY-12296S

Navtemadlin-d7 (AMG 232-d7) is the deuterium labeled Navtemadlin. Navtemadlin (AMG 232) is a potent, selective and orally available inhibitor of **p53-MDM2** interaction, with an IC_{50} of 0.6 nM. Navtemadlin binds to MDM2 with a K_d of 0.045 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NSC 146109 hydrochloride

Cat. No.: HY-108638

NSC 146109 hydrochloride is a small-molecule **p53** activator that target **MDMX** and can be used for breast cancer research. NSC 146109 hydrochloride is a pseudourea derivative, promotes breast cancer cells to undergo **apoptosis** through activating p53 and inducing expression of proapoptotic genes.



Purity: 99.60%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NSC 66811

Cat. No.: HY-14967

NSC 66811 is a **MDM2-p53** inhibitor, with a K_i of 120 nM for binding to MDM2.



Purity: 98.12%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

NSC-207895

(XI-006)

Cat. No.: HY-14714

NSC-207895 (XI-006), a DNA damaging agent, is an anticancer agent and **p53** activator.



Purity: 98.97%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NSC319726

(ZMC1)

Cat. No.: HY-18634

NSC319726 (ZMC1) is a mutant p53R175 reactivator; inhibits growth of fibroblasts expressing the p53R175 mutation (IC50 = 8 nM); shows no inhibition for p53 wild-type cells.



Purity: 98.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NSC405640

Cat. No.: HY-144105

NSC405640 is a potent inhibitor of the MDM2-**p53** interaction. NSC405640 rescues structural p53 mutations. NSC405640 selectively inhibits the growth of cell lines with wild-type p53.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NSC59984

Cat. No.: HY-19726

NSC59984 induces mutant p53 protein degradation via MDM2 and the ubiquitin-proteasome pathway. NSC59984 acts by targeting GOF-mutant p53 and stimulates p73 to restore the p53 pathway signaling.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NSC90616

Cat. No.: HY-144104

NSC90616 is a mutant **p53** rescue compound.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nutlin-3

Cat. No.: HY-50696

Nutlin-3 is a commercial available **p53-MDM2** inhibitor, with K_i of 90 nM.



Purity: 99.18%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Nutlin-3a

(Rebemadlin)

Cat. No.: HY-10029

Nutlin-3a (Rebemadlin), an active enantiomer of Nutlin-3, is a potent **murine double minute (MDM2)** inhibitor (IC_{50}=90 nM). Nutlin-3a inhibits **MDM2-p53** interactions and stabilizes the p53 protein, and induces cell **autophagy** and **apoptosis**.



Purity: 98.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Nutlin-3b

Cat. No.: HY-15335

Nutlin-3b is a **p53/MDM2** inhibitor with an IC_{50} of 13.6 μM. Nutlin-3b is 150 times less potent in binding to MDM2 than Nutlin-3a.



Purity: 99.16%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

NVP-CGM097

(CGM097)

Cat. No.: HY-15954

NVP-CGM097 is a potent and selective **MDM2** inhibitor with IC_{50} of 1.7±0.1 nM for **hMDM2**.



Purity: 98.52%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

NVP-CGM097 sulfate

(CGM097 sulfate) **Cat. No.**: HY-15954B

NVP-CGM097 sulfate is a potent and selective **MDM2** inhibitor with IC_{50} of 1.7±0.1 nM for **hMDM2**.



Purity: 98.76%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

p53 (17-26)

Cat. No.: HY-P1755

p53 (17-26) is amino acids 17 to 26 fragment of p53. p53 (17-26) is mdm-2-binding domain.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

p53 Activator 2

Cat. No.: HY-146095

p53 Activator 2 (compound 10ah) intercalats into DNA and results in significant DNA double-strand break.p53 Activator 2 increases the expression of **p53**, p-p53, CDK4, p21 to cause cell cycle arrest at G2/M phase.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

p53 and MDM2 proteins-interaction-inhibitor (chiral)

Cat. No.: HY-70027

p53 and MDM2 proteins-interaction-inhibitor (chiral) (Compound 32) is an inhibitor of the interaction between p53 and MDM2 proteins.



Purity: 98.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

p53 and MDM2 proteins-interaction-inhibitor (racemic)

Cat. No.: HY-70028

p53 and MDM2 proteins-interaction-inhibitor (racemic) (Compound 2j) is an inhibitor of the interaction between p53 and MDM2 proteins.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

p53 and MDM2 proteins-interaction-inhibitor dihydrochloride

Cat. No.: HY-70027A

p53 and MDM2 proteins-interaction-inhibitor dihydrochloride is an inhibitor of the interaction between p53 and MDM2 proteins.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 100 mg

p53-HDM2-IN-1

Cat. No.: HY-145907

p53-HDM2-IN-1 is a potent inhibitor of **p53-HDM2 protein-protein interaction**, with an IC_{50} of 0.103 μM. p53-HDM2-IN-1 can be used for the research of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

P53R3

Cat. No.: HY-122578

P53R3 is a potent **p53 reactivator** and restores sequence-specific DNA binding of p53 hot spot mutants, including $p53^{R175H}$, $p53^{R248W}$ and $p53^{R273H}$. P53R3 induces p53-dependent antiproliferative effects with much higher specificity than PRIMA-1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PhiKan 083

Cat. No.: HY-108637

PhiKan 083 is a carbazole derivative, which binds to the surface cavity and stabilizes **Y220C** (a **p53** mutant), with a K_d of 167 μM. PhiKan 083 can be used for cancer research.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

PhiKan 083 hydrochloride

Cat. No.: HY-108637A

PhiKan 083 hydrochloride is a carbazole derivative, which binds to the surface cavity and stabilizes **Y220C** (a **p53** mutant), with a K_d of 167 μM, and a relative binding affinity (K_d) of 150 μM in Ln229 cells.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pifithrin-α hydrobromide

(Pifithrin hydrobromide; PFTα hydrobromide) **Cat. No.:** HY-15484

Pifithrin-α hydrobromide is a **p53** inhibitor which blocks its transcriptional activity and prevents cells from apoptosis. Pifithrin-α hydrobromide is also an **aryl hydrocarbon receptor (AhR)** agonist.



Purity: 95.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Pifithrin-α, p-Nitro, Cyclic

(PFN-α) **Cat. No.:** HY-123076

Pifithrin-α, p-Nitro, Cyclic (PFN-α) is cell-permeable and active-form **p53** inhibitor. Pifithrin-α, p-Nitro, Cyclic is one order magnitude more active than Pifithrin-α in protecting cortical neurons exposed to Etoposide (ED_{50}=30 nM).



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Pifithrin-β

(PFT β; Cyclic Pifithrin-α) **Cat. No.:** HY-16702

Pifithrin-β (PFT β) is a potent **p53** inhibitor with an **IC_{50}** of 23 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pifithrin-β hydrobromide

(PFT β hydrobromide; Cyclic Pifithrin-α hydrobromide) **Cat. No.:** HY-16702A

Pifithrin-β hydrobromide (PFT β hydrobromide) is a potent **p53** inhibitor with an **IC_{50}** of 23 μM.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Pifithrin-μ

(PFTμ; 2-Phenylethynesulfonamide) **Cat. No.:** HY-10940

Pifithrin-μ is an inhibitor of **p53** and **HSP70**, with antitumor and neuroprotective activity.



Purity: 98.31%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg

PK11000

Cat. No.: HY-U00447

PK11000 is an **alkylating** agent, and stabilizes the DNA-binding domain of both WT and mutant **p53** by covalent cysteine modification, without compromising DNA binding.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

PK11007

Cat. No.: HY-128784

PK11007 is a mild thiol alkylator with anticancer activity. PK11007 stabilizes **p53** via selective alkylation of two surface-exposed cysteines without compromising its DNA binding activity. PK11007 induces mutant **p53** cancer cell death by increasing **reactive oxygen species (ROS)** levels.



Purity: 99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PK9327

Cat. No.: HY-145937

PK9327 is a small-molecule stabilizer targeting cavity-creating **p53** cancer mutations.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PRIMA-1

(NSC-281668) **Cat. No.:** HY-19980A

PRIMA-1 (NSC-281668) is a mutant **p53** reactivator, restores the sensitivity of TP53 mutant-type thyroid cancer cells to the histone methylation inhibitor 3-Deazaneplanocin A.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

PROTAC MDM2 Degrader-1

Cat. No.: HY-128840

PROTAC MDM2 Degrader-1 is a **MDM2** degrader based on **PROTAC** technology. PROTAC MDM2 Degrader-1 composes of a potent MDM2 inhibitor, linker, and the MDM2 ligand for E3 ubiquitin ligase.



Purity: 98.39%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg

PROTAC MDM2 Degrader-2

Cat. No.: HY-128841

PROTAC MDM2 Degrader-2 is a **MDM2** degrader based on **PROTAC** technology. PROTAC MDM2 Degrader-2 composes of a potent MDM2 inhibitor, linker, and the MDM2 ligand for E3 ubiquitin ligase.



Purity: 98.50%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg

PROTAC MDM2 Degrader-3

Cat. No.: HY-128842

PROTAC MDM2 Degrader-3 is a **MDM2** degrader based on **PROTAC** technology. PROTAC MDM2 Degrader-3 composes of a potent MDM2 inhibitor, linker, and the MDM2 ligand for E3 ubiquitin ligase.

Purity: 98.69%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

PROTAC MDM2 Degrader-4

Cat. No.: HY-128843

PROTAC MDM2 Degrader-4 is a **MDM2** degrader based on **PROTAC** technology. PROTAC MDM2 Degrader-4 composes of a potent MDM2 inhibitor, linker, and the MDM2 ligand for E3 ubiquitin ligase.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ReACp53

Cat. No.: HY-P0121

ReACp53 could inhibit p53 amyloid formation and rescue p53 function in cancer cell lines.

H-RRRRRRRRRRPILTRITLE-OH

Purity: 99.39%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

RG7112

(RO5045337)

Cat. No.: HY-10959

RG7112 is a potent, selective, first clinical, orally active and blood-brain barrier crossed **MDM2-p53** inhibitor, with an IC_{50} of 18 nM and a K_D of 11 nM for binding to MDM2.



Purity: 99.91%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RITA

(NSC 652287)

Cat. No.: HY-13424

RITA is an inhibitor of **p53-HDM-2 interaction**, binds to p53dN, with a K_d of 1.5 nM, and also induces **DNA-DNA cross-links**.



Purity: 99.45%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

RO-5963

Cat. No.: HY-120086

RO-5963 is a dual **p53-MDM2** and **p53-MDMX** inhibitor with IC_{50}s of ~17 nM and ~24 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RO8994

Cat. No.: HY-16999

RO8994 is a highly potent and selective series of spiroindolinone small-molecule MDM2 inhibitor, with IC50 of 5 nM (HTRF binding assays) and 20 nM (MTT proliferation assays).



Purity: 99.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Roslin 2 bromide

(Benzylhexamethylenetetramine bromide)

Cat. No.: HY-A0280

Roslin 2 bromide (Benzylhexamethylenetetramine bromide) is a **p53** reactivator with anticancer effects. Roslin 2 bromide binds FAK, disrupts the binding of FAK and p53.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

S100A2-p53-IN-1

Cat. No.: HY-145900

S100A2-p53-IN-1 (compound 51) is a **S100A2-p53** interactions inhibitor. S100A2 is a Ca^{2+} binding protein with implications in cell signaling and is known to be upregulated in pancreatic cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sanggenol L

Cat. No.: HY-N2602

Sanggenol L induces caspase-dependent and caspase-independent apoptosis in melanoma skin cancer cells. Sanggenol L induces of apoptosis via suppression of **PI3K/Akt/mTOR** signaling and cell cycle arrest via activation of **p53** in p.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

SAR405838

(MI-77301)

Cat. No.: HY-18986

SAR405838 (MI-77301), an analog of MI-773, is a highly potent and selective **MDM2-p53** interaction inhibitor. SAR405838 binds to MDM2 with a K_i of 0.88 nM. SAR405838 induces **apoptosis** and has potent antitumor activity.



Purity: 95.02%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SCH529074

Cat. No.: HY-110088

SCH529074 is a potent and orally active **p53** activator. SCH529074 binds specifically and conformation-dependently to p53 DBD (DNA binding domain) with a K_i of 1-2 μM in a saturable manner.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Serdemetan

(JNJ-26854165)

Cat. No.: HY-12025

Serdemetan(JNJ-26854165) acts as a HDM2 ubiquitin ligase antagonist and also induces early apoptosis in p53 wild-type cells, inhibits cellular proliferation followed by delayed apoptosis in the absence of functional p53.



Purity: 99.23%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Siremadlin

(NVP-HDM201; HDM201)

Cat. No.: HY-18658

Siremadlin (NVP-HDM201) is a potent, orally bioavailable and highly specific **p53-MDM2** interaction inhibitor.



Purity: 99.82%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

SJ-172550

Cat. No.: HY-16664

SJ-172550 is a small molecule inhibitor of **MDMX**; competes for the wild type p53 peptide binding to MDMX with an EC_{50} of 5 μM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Solasodine

(Purapuridine; Solancarpidine; Solasodin)

Cat. No.: HY-N0068

Solasodine (Purapuridine) is a steroidal alkaloid that occurs in plants of the Solanaceae family. Solasodine has neuroprotective, antifungal, hypotensive, anticancer, antiatherosclerotic, antiandrogenic and anti-inflammatory activities.



Purity: 98.86%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg, 100 mg

SP-141

Cat. No.: HY-110182

SP-141 is a specific inhibitor of **MDM2**. SP-141 promotes MDM2 auto-ubiquitination and degradation. SP-141 might be used for the research of pancreatic cancer and breast cancer cells.



Purity: 99.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tenovin-1

Cat. No.: HY-13423

Tenovin-1, a **p53** activator, protects p53 from MDM2-mediated degradation. Tenovin-1 acts through inhibition of the protein-deacetylating activities of SirT1 and SirT2. Tenovin-1 is also a **dihydroorotate dehydrogenase (DHODH)** inhibitor.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg

Tenovin-3

Cat. No.: HY-19339

Tenovin-3 is a **p53** activator.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Tenovin-6

Cat. No.: HY-15510

Tenovin-6, an analog of Tenovin-1 (HY-13423), is an activator of **p53** transcriptional activity. Tenovin-6 inhibits the protein deacetylase activities of purified human SIRT1, SIRT2, and SIRT3 with IC_{50}s of 21 μM, 10 μM, and 67 μM, respectively.



Purity: 98.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Tenovin-6 Hydrochloride

Cat. No.: HY-15510B

Tenovin-6 Hydrochloride, an analog of Tenovin-1 (HY-13423), is an activator of **p53** transcriptional activity.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Teprasiran

(QPI-1002)

Cat. No.: HY-132595

Teprasiran (QPI-1002) is a small interfering RNA that temporarily inhibits **p53**-mediated cell death that underlies acute kidney injury (AKI).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Triglycidyl isocyanurate

(TGIC; Teroxirone)

Cat. No.: HY-W011434

Triglycidyl isocyanurate (TGIC; Teroxirone) is a triazene triepoxide with antiangiogenic and antineoplastic activities. Triglycidyl isocyanurate inhibits the growth of non-small-cell-lung cancer cells via **p53** activation.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg, 1 g

UC2288

Cat. No.: HY-112780

UC2288 is a novel, cell-permeable, and orally active **p21** attenuator (relatively selective activity for p21), which is synthesized based Sorafenib (HY-10201).



Purity: 99.92%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 250 mg

Verminoside

Cat. No.: HY-N1094

Verminoside is an iridoid isolated from Kigelia africana, exhibits anti-inflammatory and remarkable antioxidant activity with a radical-scavenging activity of 2.5 μg/mL. The genotoxicity of Verminoside on human lymphocytes is associated with elevated levels of **PARP-1** and **p53** proteins.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

YH239-EE

Cat. No.: HY-12287

YH239-EE, ethyl ester of the free carboxylic acid compound YH239, is a potent p53-MDM2 antagonizing and apoptosis-inducing agent. IC50 value: Target: MDM2/p53 YH239-EE inhibits the growth of OCI-AML-3 cells with wild type p53 by inhibiting the p53-MDM2 interaction.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Ziyuglycoside I

Cat. No.: HY-N0331

Ziyuglycoside I isolated from S. officinalis root, has anti-wrinkle activity, and increases the expression of type I collagen. Ziyuglycoside I could be used as an active ingredient for cosmetics.



Purity: 99.47%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg